Back to results
US 2026/0078403 A1Published application
Zikv-based gene delivery system
AssigneeThe Regents of the University of California
InventorsAlysson Renato Muotri, Ronaldo Borges
Life of this patent
Estimating the term…
Abstract
The disclosure provides for recombinantly modified Zika-based vectors that can be used in gene therapy applications.
Claims30
A recombinantly modified Zika virus (ZIKV)-based particle or vector, comprising:
- an RNA genome having from 5′ to 3′:
- a 5′ UTR from a Flavivirus;
- one or more heterologous genes comprising a transgene cassette inserted into or replacing coding sequences for genes selected from the group consisting of a capsid gene (C gene), a pRM/M gene, an envelope gene (E gene), an NS1 gene, and any combination thereof;
- one or more genes for nonstructural proteins NS1, NS2A, NS2B, NS3, NS4A, NS4B, and/or NS5 from ZIKV;
- and
- a 3′ UTR from a Flavivirus.
3 more elements
(canceled)
-13. (canceled)
(canceled)
-32. (canceled)
Dependencies are inferred from the claim text.